Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

نویسندگان

  • Maria Elena Maccari
  • Hassan Abolhassani
  • Asghar Aghamohammadi
  • Alessandro Aiuti
  • Olga Aleinikova
  • Catherine Bangs
  • Safa Baris
  • Federica Barzaghi
  • Helen Baxendale
  • Matthew Buckland
  • Siobhan O. Burns
  • Caterina Cancrini
  • Andrew Cant
  • Pascal Cathébras
  • Marina Cavazzana
  • Anita Chandra
  • Francesca Conti
  • Tanya Coulter
  • Lisa A. Devlin
  • J. David M. Edgar
  • Saul Faust
  • Alain Fischer
  • Marina Garcia Prat
  • Lennart Hammarström
  • Maximilian Heeg
  • Stephen Jolles
  • Elif Karakoc-Aydiner
  • Gerhard Kindle
  • Ayca Kiykim
  • Dinakantha Kumararatne
  • Bodo Grimbacher
  • Hilary Longhurst
  • Nizar Mahlaoui
  • Tomas Milota
  • Fernando Moreira
  • Despina Moshous
  • Anna Mukhina
  • Olaf Neth
  • Benedicte Neven
  • Alexandra Nieters
  • Peter Olbrich
  • Ahmet Ozen
  • Jana Pachlopnik Schmid
  • Capucine Picard
  • Seraina Prader
  • William Rae
  • Janine Reichenbach
  • Stephan Rusch
  • Sinisa Savic
  • Alessia Scarselli
  • Raphael Scheible
  • Anna Sediva
  • Svetlana O. Sharapova
  • Anna Shcherbina
  • Mary Slatter
  • Pere Soler-Palacin
  • Aurelie Stanislas
  • Felipe Suarez
  • Francesca Tucci
  • Annette Uhlmann
  • Joris van Montfrans
  • Klaus Warnatz
  • Anthony Peter Williams
  • Phil Wood
  • Sven Kracker
  • Alison Mary Condliffe
  • Stephan Ehl
چکیده

Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2-3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Electroacupuncture attenuates chronic fibromyalgia pain through the phosphorylated phosphoinositide 3-kinase signaling pathway in the mouse brain

Objective(s): Fibromyalgia (FM) is a central nervous system disorder characterized by widespread mechanical hyperalgesia due to unknown mechanisms. Several inflammatory mediators, such as interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor, are increased in the serum of FM patients. Although medications including pregabalin, duloxetine, and milnacipran are used...

متن کامل

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility. Recent studies show that PI3K may also play a role in the development of resistance to currently available therapies. In a broad range of cancers, various components of the phosphoinositide 3-kinase signaling axis are genetically modified,...

متن کامل

Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome

The activated phosphoinositide 3-kinase δ syndrome (APDS), also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI), is a combined immunodeficiency syndrome caused by gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD (encoding p110δ: APDS1 or PASLI-CD) and PIK3R1 (encoding p85α: APDS2 or PASLI-R1). While the d...

متن کامل

Inhibition of Protein Kinase C Delta Attenuates Allergic Airway Inflammation through Suppression of PI3K/Akt/mTOR/HIF-1 Alpha/VEGF Pathway

Vascular endothelial growth factor (VEGF) is supposed to contribute to the pathogenesis of allergic airway disease. VEGF expression is regulated by a variety of stimuli such as nitric oxide, growth factors, and hypoxia-inducible factor-1 alpha (HIF-1α). Recently, inhibition of the mammalian target of rapamycin (mTOR) has been shown to alleviate cardinal asthmatic features, including airway hype...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 9  شماره 

صفحات  -

تاریخ انتشار 2018